Jui-Ming Chen1, Cheng-Wei Chang2, Tzu-Hao Chang3, Chi-Chang Hsu4, Jorng-Tzong Horng5, Wayne H-H Sheu6. 1. Department of Endocrinology and Metabolism, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan ; Department of Biomedical Informatics, Asia University, Taichung, Taiwan ; Department of Gerontechnology and Service Management, Nan Kai University of Technology, Nantou, Taiwan. 2. Department of Information Management, Hsing Wu University, New Taipei City, Taiwan. 3. Graduate Institute of Biomedical Informatics, Taipei Medical University, Taipei, Taiwan. 4. Department of Computer Science and Information Engineering, National Central University, Chungli, Taiwan. 5. Department of Gerontechnology and Service Management, Nan Kai University of Technology, Nantou, Taiwan ; Department of Computer Science and Information Engineering, National Central University, Chungli, Taiwan. 6. Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan ; School of Medicine, National Defense Medical Center, Taipei, Taiwan ; School of Medicine, National Yang-Ming University, Taipei, Taiwan ; Institute of Medical Technology, National Chung-Hsing University, Taichung, Taiwan.
Abstract
BACKGROUND: Patients with Type 2 diabetes (T2DM) are prone to develop dementia. Results from a recent study indicated that statin users had lower chance of developing incident dementia. However there is little information on the potential benefits of statin use on dementia in patients with T2DM cohort. METHOD: A population-based retrospective study using a nationwide cohort of National Health Insurance Research Database in Taiwan was performed. T2DM cohort with regular use of statins was followed up to 8 years. Multivariate cox-proportional hazards regression model was used to estimate the association between statin use and incidence of dementia including Alzheimer's disease and non-Alzheimer dementia after adjusting for several potential confounders. RESULTS: Among 28,321 patients diagnosed with T2DM age above 50 and without history of dementia before 2000/1/1, 15,770 patients who had never used statin and 2,400 patients who regularly used statin drugs were enrolled. After adjusting for age group, gender, CCI (Charlson-Deyo comorbidity index) group, stroke types and anti-diabetic drugs, regular statin use was associated with a decreased risk of developing incident Alzheimer's disease dementia (adjusted HR: 0.48, 95% CI 0.30 - 0.76, p<0.001), but not in non-Alzheimer dementia (adjusted HR: 1.07, 95% CI 0.54-2.12 p = 0.844) in patients with T2DM. Further analysis showed significant protective effects of the use of atorvastatin and simvastatin. CONCLUSION: Regular use of statins might decrease the risk of developing Alzheimer's disease in patients with T2DM while no benefit was observed in non-Alzheimer dementia. Among statins, both atorvastatin and simvastatin showed significant benefits.
BACKGROUND:Patients with Type 2 diabetes (T2DM) are prone to develop dementia. Results from a recent study indicated that statin users had lower chance of developing incident dementia. However there is little information on the potential benefits of statin use on dementia in patients with T2DM cohort. METHOD: A population-based retrospective study using a nationwide cohort of National Health Insurance Research Database in Taiwan was performed. T2DM cohort with regular use of statins was followed up to 8 years. Multivariate cox-proportional hazards regression model was used to estimate the association between statin use and incidence of dementia including Alzheimer's disease and non-Alzheimer dementia after adjusting for several potential confounders. RESULTS: Among 28,321 patients diagnosed with T2DM age above 50 and without history of dementia before 2000/1/1, 15,770 patients who had never used statin and 2,400 patients who regularly used statin drugs were enrolled. After adjusting for age group, gender, CCI (Charlson-Deyo comorbidity index) group, stroke types and anti-diabetic drugs, regular statin use was associated with a decreased risk of developing incident Alzheimer's disease dementia (adjusted HR: 0.48, 95% CI 0.30 - 0.76, p<0.001), but not in non-Alzheimer dementia (adjusted HR: 1.07, 95% CI 0.54-2.12 p = 0.844) in patients with T2DM. Further analysis showed significant protective effects of the use of atorvastatin and simvastatin. CONCLUSION: Regular use of statins might decrease the risk of developing Alzheimer's disease in patients with T2DM while no benefit was observed in non-Alzheimer dementia. Among statins, both atorvastatin and simvastatin showed significant benefits.
Authors: D Larry Sparks; Marwan N Sabbagh; Donald J Connor; Jean Lopez; Lenore J Launer; Patrick Browne; Dawn Wasser; Sherry Johnson-Traver; Jeff Lochhead; Chuck Ziolwolski Journal: Arch Neurol Date: 2005-05
Authors: Thomas D Rea; John C Breitner; Bruce M Psaty; Annette L Fitzpatrick; Oscar L Lopez; Anne B Newman; William R Hazzard; Peter P Zandi; Gregory L Burke; Constantine G Lyketsos; Charles Bernick; Lewis H Kuller Journal: Arch Neurol Date: 2005-07
Authors: G Li; E B Larson; J A Sonnen; J B Shofer; E C Petrie; A Schantz; E R Peskind; M A Raskind; J C S Breitner; T J Montine Journal: Neurology Date: 2007-08-28 Impact factor: 9.910
Authors: M D M Haag; A Hofman; P J Koudstaal; B H C Stricker; M M B Breteler Journal: J Neurol Neurosurg Psychiatry Date: 2008-10-17 Impact factor: 10.154
Authors: Geert Jan Biessels; Salka Staekenborg; Eric Brunner; Carol Brayne; Philip Scheltens Journal: Lancet Neurol Date: 2006-01 Impact factor: 44.182